For years, scientists and physicians have known that mRNA-based COVID-19 vaccines, while remarkably effective and broadly safe, carry a small but real risk of causing myocarditis — inflammation of the heart muscle — particularly in young men and adolescents. Now, a research team at Stanford Medicine has identified the precise biological mechanism behind this phenomenon, offering not only a clearer scientific picture but also a potential path toward preventing the condition altogether.
The findings, published in Science Translational Medicine, represent a significant step forward in understanding how the immune system can, in rare cases, turn its powerful defenses against the very organ it is meant to protect.
A Rare but Real Risk
Before diving into the science, it is worth putting the risk in perspective. mRNA COVID-19 vaccines have been administered several billion times worldwide and have been scrutinized extensively for safety. The rate of vaccine-associated myocarditis after a first dose is approximately one in every 140,000 people vaccinated. That figure rises to roughly one in 32,000 after a second dose. Among male vaccinees aged 30 and under — the group most affected — the rate climbs to about one in 16,750.
These numbers are small, but they are not zero. And for the individuals who experience serious cases, the consequences can be significant, including hospitalizations, intensive care admissions, and in very rare instances, death.
Joseph Wu, MD, PhD, director of the Stanford Cardiovascular Institute and a senior author of the study, is quick to emphasize that the condition is usually manageable. “It’s not a heart attack in the traditional sense,” he said. “There’s no blockage of blood vessels as found in most common heart attacks. When symptoms are mild and the inflammation hasn’t caused structural damage to the heart, we just observe these patients to make sure they recover.”
He is equally quick to note the broader context: a COVID-19 infection itself is approximately ten times more likely to cause myocarditis than the mRNA vaccine designed to prevent it — on top of all the other serious complications the illness can bring.
Following the Trail of Two Proteins
The Stanford team began their investigation by analyzing blood samples from people who had been vaccinated against COVID-19, comparing those who developed myocarditis with those who did not. Two proteins stood out prominently in the blood of those who experienced heart inflammation: CXCL10 and IFN-gamma.
Both belong to a category of molecules called cytokines — chemical messengers that immune cells use to communicate with one another. Wu described the pair as operating like a tag team, each playing a distinct but complementary role in driving the inflammatory process that ultimately harms the heart.
To understand how these proteins are produced, the researchers turned to laboratory experiments. They generated human immune cells called macrophages — aggressive frontline defenders of the immune system — and exposed them to mRNA vaccines in a controlled dish setting. The macrophages responded by releasing a variety of cytokines, with CXCL10 produced in particularly notable quantities.
When a second type of immune cell — T cells, which serve as roving sentinels capable of recognizing specific threats and amplifying immune responses — was introduced to the dish, or even when T cells were simply placed in the fluid in which vaccine-treated macrophages had been bathed, IFN-gamma output increased dramatically. T cells exposed to the vaccine alone, without the macrophage-conditioned environment, produced only ordinary amounts of IFN-gamma. This finding established a clear sequence: macrophages are the primary source of CXCL10, and T cells are the primary source of IFN-gamma, with the latter depending on signals from the former.
Confirming the Damage in Living Systems
To confirm that this two-protein cascade actually causes cardiac injury, the researchers turned to mouse models. Young male mice were vaccinated and subsequently showed elevated levels of cardiac troponin — a protein released into the bloodstream when heart muscle cells are damaged and a standard clinical marker used to diagnose heart injury in humans.
Examination of the mice’s heart tissue revealed infiltration by macrophages and neutrophils, another class of aggressive immune cells. This kind of immune cell invasion into heart tissue is also observed in human patients with post-vaccination myocarditis. The problem with these cells is that, in their eagerness to fight perceived threats, they can cause collateral damage to healthy tissue — including the delicate cells of the heart muscle.
When the researchers blocked the activity of CXCL10 and IFN-gamma, this infiltration was substantially reduced, and cardiac troponin levels dropped, even as the overall immune response to the vaccine remained largely intact. This was a critical finding: it suggested that the inflammatory damage to the heart might be separable from the vaccine’s protective immune function.
The team went further, using a cutting-edge technology developed in Wu’s laboratory. Human skin or blood cells can be transformed into blank stem-like cells and then guided to differentiate into heart muscle cells, macrophages, and the cells that line blood vessels. These cells can then be assembled into tiny spherical structures that mimic the beating, contracting behavior of actual heart tissue — what the researchers call “cardiac spheroids.”
When these cardiac spheroids were treated with cytokine-enriched fluid from vaccine-stimulated immune cells, markers of cardiac stress increased significantly and the spheroids’ ability to contract rhythmically was impaired. When cytokine inhibitors were applied, much of this damage was reversed.
A Soybean Compound Enters the Picture
Having mapped out the mechanism of injury, Wu and his team turned to a question with practical implications: could anything be done to prevent it?
Wu had a hypothesis rooted in an earlier line of research. He had previously studied a compound called genistein — a naturally occurring, mildly estrogen-like substance found in soybeans — and found it to have notable anti-inflammatory properties. That work, published in the journal Cell in 2022, had shown genistein’s ability to protect blood vessels and heart tissue from a different kind of inflammatory insult.
The connection to myocarditis seemed plausible for several reasons. The condition disproportionately affects males, and estrogen is known to have anti-inflammatory effects. Genistein, which mimics estrogen only weakly, might offer some of those protective benefits without the hormonal side effects of stronger compounds.
Wu’s team ran a parallel series of experiments in which cells, cardiac spheroids, and mice were pretreated with genistein before being exposed to the vaccine or the CXCL10 and IFN-gamma combination. In each case, genistein significantly reduced the damaging effects on heart tissue.
The version of genistein used in these experiments was considerably purer and more concentrated than what is available in typical dietary supplements. Wu acknowledged this distinction while noting the compound’s fundamental safety profile. “Nobody ever overdosed on tofu,” he remarked.
Broader Implications for mRNA Technology
The findings carry implications that extend beyond COVID-19 vaccination. The researchers suggest that elevated inflammatory cytokine signaling may be a general property of mRNA-based vaccines — a consequence of the body’s fundamental immune response to foreign genetic material.
IFN-gamma, in particular, is part of a core defense mechanism against viruses and other pathogens. It is essential to mounting an effective immune response, but when produced in large quantities, it can trigger inflammation that damages structural proteins within the heart muscle. This kind of heightened cytokine activity may affect organs beyond the heart as well, with preliminary evidence pointing to similar effects in the lungs, liver, and kidneys.
Wu also pointed out that myocarditis is not unique to mRNA COVID-19 vaccines — other vaccine types can also cause it, and COVID-19 infection itself is a more potent trigger. However, the intense public attention on COVID-19 vaccines has meant that even mild cardiac symptoms following vaccination are more likely to be investigated and diagnosed, creating a more complete picture of risk than exists for other vaccines.
What Comes Next
The research opens several avenues for future work. One important direction is developing strategies to reduce the risk of myocarditis without compromising the protective immune response that makes mRNA vaccines so effective. Genistein represents one candidate, though the path from laboratory findings to clinical application involves extensive additional research.
Another area of interest is understanding why young males are disproportionately affected. The role of hormonal differences in shaping immune responses is an active area of investigation, and genistein’s estrogen-like activity hints at one possible dimension of this story.
For now, the Stanford team’s findings provide the clearest mechanistic account yet of why mRNA COVID-19 vaccines occasionally cause myocarditis — and suggest that the condition, while serious in some cases, may be addressable through targeted interventions that preserve the vaccine’s core benefits while protecting the heart.
The study was supported by the National Institutes of Health and the Gootter-Jensen Foundation.